@Article{W. Pęksa2025,
journal="Lekarz POZ",
issn="2450-3517",
volume="11",
number="3",
year="2025",
title="High levels of LDL cholesterol – management algorithms",
abstract="Hypercholesterolemia, or elevated levels of LDL fraction cholesterol, is one of the major cardiovascular (CV) risk factors. For this lipid metabolism disorder, pharmacotherapy is used in addition to the use of non-pharmacological methods (performing regular aerobic physical activity, eating a diet low in saturated fat, maintaining body weight at normal levels, not smoking tobacco products). The 2021 European Society of Cardiology expert guideline on CV prevention proposes a hypolipemic treatment pathway that should be followed when treating patients with hypercholesterolemia. Treatment usually begins with the inclusion of a potent HMG-CoA reductase inhibitor (statin). If treatment with a statin alone is insufficient to achieve the intended therapeutic effect, a drug that works by another mechanism is added to the therapy: ezetimibe or one of the PCSK9 inhibitors. If a combination of statin and ezetimibe is used, combination formulations containing 2 active substances in one tablet can be used. This paper discusses the management of hypercholesterolemia therapy in daily clinical practice, depending on the CV risk of patients.",
author="W. Pęksa, Jan",
pages="180--189",
url="https://www.termedia.pl/High-levels-of-LDL-cholesterol-management-algorithms,98,56649,1,1.html"
}